Nikhil Prasad Fact checked by:Thailand Medical News Team Jul 07, 2026 59 minutes ago
Medical News: A Landmark Moment in Cancer Treatment
A major breakthrough in cancer medicine has arrived with the approval of vepdegestrant (formerly known as ARV-471), the world's first PROTAC-based drug to reach the market. The approval marks the beginning of an entirely new class of medicines that work differently from conventional drugs by eliminating harmful proteins instead of simply blocking them. The review was conducted by researchers from the Department of Pharmaceutical Chemistry, University of Debrecen, and the Doctoral School of Pharmaceutical Sciences, University of Debrecen, Hungary.
The first approved PROTAC drug destroys cancer-driving proteins instead of simply blocking them, offering
fresh hope for patients with advanced breast cancer.
Vepdegestrant has been approved for adults with advanced or metastatic breast cancer carrying ESR1 gene mutations after previous endocrine therapy has failed. This milestone could reshape future cancer treatment strategies.
How the Drug Works
Most existing breast cancer medicines slow cancer growth by blocking estrogen signals. However, many tumors eventually become resistant through genetic mutations that allow cancer cells to continue growing.
Vepdegestrant uses an entirely different strategy. It belongs to a new family of medicines called PROTACs, or Proteolysis Targeting Chimeras. Instead of merely attaching to the estrogen receptor, the drug recruits the cell's own protein disposal machinery to completely destroy the receptor. Once the unwanted protein is removed, the drug molecule is released and can repeat the process on additional targets, making it highly efficient.
This unique "destroy rather than block" approach also allows PROTAC drugs to attack proteins previously considered impossible to target.
Strong Results in Laboratory and Clinical Studies
Researchers found that vepdegestrant rapidly removed up to 95 percent of estrogen receptors from breast cancer cells in laboratory experiments. It remained highly effective against several important ESR1 mutations that commonly cause resistance to older hormone therapies.
Animal studies were equally impressive. Tumor growth was dramatically reduced, with some experimental models showing complete tumor regression. The drug also performed better than the older drug fulvestrant in several resistant breast cancer models and worked well alongside CDK4/6 inhibitors and other targeted cancer medicines.
This
Medical News report highlights that one of the drug's biggest advantages is its catalytic action. Unlike traditional medicines that remain attached to a single target, one vepdegestrant molecule can destroy multiple estrogen receptors, potentially making treatment more effective while using lower amounts of drug.
Human clinical trials also produced encouraging findings. In patients carrying ESR1 mutations, progression-free survival increased to about five months compared to just over two months for patients receiving fulvestrant. R
esponse rates were also substantially higher, demonstrating that the drug offers meaningful benefits for carefully selected patients.
Challenges Still Remain
Despite its success, vepdegestrant is not without limitations.
The drug is a relatively large and chemically complex molecule, making it more difficult for the body to absorb. Scientists overcame many of these challenges through careful molecular design, including a rigid linker that improved stability and oral availability.
Researchers also identified several safety issues requiring monitoring. The most common side effects included fatigue, nausea, joint pain, increased liver enzymes and hot flashes. Some patients developed low white blood cell counts, while a small number experienced prolongation of the QT interval, an electrical change in the heart that requires medical monitoring. Drug interactions with medications processed through certain liver enzymes or transported by P-glycoprotein may also require careful management.
A New Era for Protein-Degrading Medicines
The approval of vepdegestrant represents much more than another breast cancer therapy. It validates decades of research into targeted protein degradation and opens the door for dozens of other PROTAC medicines now being developed for cancer and other diseases. Researchers believe future versions could target proteins previously regarded as "undruggable," potentially expanding treatment options far beyond breast cancer.
Conclusion
The approval of vepdegestrant marks a historic advance in modern medicine by introducing the first clinically approved PROTAC therapy. While continued research is needed to better understand its long-term safety, resistance patterns and broader clinical applications, its ability to selectively destroy disease-driving proteins rather than simply inhibit them may fundamentally change how many cancers and other difficult diseases are treated in the years ahead.
The study findings were published in the peer reviewed journal: Pharmaceutics.
https://www.mdpi.com/1999-4923/18/7/827
For the latest on PROTAC Drugs, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/med-news
https://www.thailandmedical.news/articles/cancer
https://www.thailandmedical.news/news/scientists-develop-virus-fighting-protein-destruction-technology
Share
Tweet
Share
